Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (OTC: HALB) generates a steady stream of news centered on its healthcare technology initiatives, research collaborations, and funding developments. Investors and observers following HALB news can expect updates on traumatic brain injury (TBI) research, PTSD and mental health programs, AI-driven behavioral platforms, and partnerships with medical and technology organizations.
Recent press releases highlight Halberd’s work with Mississippi State University on a proprietary nasal spray intended to mitigate the effects of TBI, including plans for advanced Phase-2 animal studies. News items also cover the company’s acquisition and development of NeuroSense AI, a behavioral intelligence platform that combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered interpretation for preclinical TBI and neurological research.
Another major theme in HALB news is its LDX and WatchDawg programs for PTSD, suicidal ideation, and related mental health challenges, particularly among veterans. Halberd and its partners report pilot study results using LDX-based therapies, nutraceuticals, yoga and meditation, and continuous wearable monitoring via Athena GTX’s technology. Announcements describe plans for larger clinical studies, solicitations for nephrologists and clinicians, and cooperative efforts with Athena Telemedicine Partners, LLC.
News releases also discuss funding and contract developments, including a substantial contract commitment involving Defense Atomics Corporation to support combined CRISPR/nanotechnology stem cell treatment with Halberd’s LDX protocol and WatchDawg monitoring. Readers of HALB news can use this page to follow progress on government contract proposals, private investment efforts, regulatory planning, and technical milestones in AI-powered healthcare platforms.
For anyone tracking HALB stock or its healthcare projects, the news feed provides context on how Halberd’s research programs, partnerships, and technology demonstrations evolve over time.
Halberd Corporation (OTC PINK:HALB) announced that it has successfully eradicated all antibiotic-resistant E. coli strains supplied by the CDC ahead of a meeting scheduled for March 29, 2023. Utilizing its patented extracorporeal method combined with metallic nanoparticles, over 90% of the bacteria was eliminated in less than 10 minutes. The company is also testing Klebsiella pneumoniae strains and expects results prior to the CDC meeting. Experts praised the rapid pathogen elimination capabilities, noting minimal adverse effects due to the process being outside the body. Halberd's innovative technology aims to advance therapeutic applications.
Halberd Corporation (OTC PINK:HALB) announced its successful eradication of over 90% of antibiotic-resistant E. coli and Candida auris in under 10 minutes using its patented extracorporeal laser eradication process. With a meeting scheduled with CDC representatives on March 29, 2023, Halberd is set to present these breakthroughs. The technology has already shown success with 12 of the 18 E. coli strains and 4 of the 20 Candida auris strains from the CDC. The company aims to further develop this technology and engage with government agencies and potential partners.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eradicating 99.5% of antibiotic-resistant E. coli in vitro within 10 minutes using a patented laser method combined with metallic nanoparticles. This breakthrough, demonstrated with strains provided by the CDC, may revolutionize healthcare by enabling faster treatments and reducing hospitalizations without antibiotics. The ongoing research aims to continue testing and optimizing the technology for commercial application, with intentions to present findings to government agencies.
Halberd Corporation announced a breakthrough in treating Candida auris, a multidrug-resistant fungal pathogen, using a novel extracorporeal method that combines lasers and metallic nanoparticles. This method has shown success in eradicating the fungus in as little as 5 minutes. Dr. Cooper from Youngstown State University emphasized the treatment's potential to mitigate the public health threat posed by such infections. Halberd has also previously demonstrated similar effectiveness against Escherichia coli and antibiotic-resistant bacteria, reinforcing its technology's versatility and potential impact on healthcare costs and patient outcomes.
Halberd Corporation (OTC PINK:HALB) recently showcased its innovative extracorporeal laser eradication process, successfully eliminating antibiotic-resistant bacteria from CDC samples. Conducted at Youngstown State University (YSU), the research led by Professors Dr. Chester Cooper and Dr. W. Gregg Sturrus, emphasizes the effectiveness of their method, which eradicates targeted bacteria in under ten minutes. Halberd's patented technology presents a significant advancement over traditional antibiotic treatments, which often require ten days. The company aims to continue demonstrating the efficacy of its process against various pathogens, potentially revolutionizing future medical treatments.
Halberd Corporation (OTC PINK:HALB) announced animal testing of its patent-pending nasal spray at Mississippi State University to address the effects of Traumatic Brain Injury (TBI). This research follows successful in vitro results in collaboration with Youngstown State University and aims to mitigate TBI-related neurological complications such as PTSD. The triple-action nasal spray can be administered promptly post-injury to potentially reduce long-term damage. Funding for the animal testing program has been secured, with Dr. Russell Carr overseeing the research.
Halberd Corporation (OTC PINK:HALB) has partnered with Mississippi State University to conduct animal testing on novel therapies aimed at mitigating traumatic brain injury effects. The research will be led by the College of Veterinary Medicine and the Department of Biomedical Engineering at the university. Dr. Russell Carr expressed enthusiasm for the collaboration's potential outcomes. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and filed 22 related applications to enhance shareholder value. Further details regarding the testing scope and timeline are expected to follow.
Halberd Corporation (OTC PINK:HALB) made significant strides in the second half of 2022, including a 44.4% enhancement in COVID-19 antibody effectiveness and the establishment of Halberd Cancer Therapeutics, LTD. The company demonstrated control over PD-1, a key cancer protein, and formed strategic alliances to develop longevity treatments. Halberd's monoclonal antibody showed efficacy against antibiotic-resistant bacteria. The firm aims to restore compliance with SEC filing and is pursuing government contracts. Leadership focuses on R&D to secure future partnerships with Big Pharma.
Halberd Corporation (OTC PINK:HALB) has received antibiotic-resistant bacteria (ARB) strains from the CDC for testing its laser eradication technology. Previously reported successes on multiple Gram-Negative bacteria have paved the way for this new phase of testing. The CDC's collaboration emphasizes the potential military applications against bio-weapons. CEO William A. Hartman highlights the significance of this partnership for national safety and the company's interests. Halberd has made strides in intellectual property with multiple patents and pending applications.
Halberd Corporation has reported the successful application of its patented methodology for Cancer Antigen Eradication Treatment. CEO William Hartman and CTO Mitchell Felder discussed these groundbreaking achievements in an interview. The company's approach involves controlling cancer antigen levels, specifically CTLA-4, to enhance immune response without harmful side effects. This extracorporeal method aims to minimize drug-related fatalities, with over 100,000 deaths annually in the U.S. attributed to medication side effects. Halberd is progressing from in-vitro to in-vivo testing, seeking to advance its innovative treatment.